Gabapentin addiction is easy to miss because the drug comes from a doctor.

Signs of gabapentin addiction are recognisable behavioural and physical patterns indicating compulsive use despite harm. Gabapentin, sold under the brand name Neurontin, is prescribed for nerve pain, epilepsy, restless legs syndrome, and, off-label, for anxiety and sleep difficulties. The gap between therapeutic use and problematic use is not always obvious, even to the person taking it.

Dependence can develop at doses well above the prescribed range, particularly with long-term use. NIDA's overview of drug misuse and addiction identifies a substance use disorder through eleven criteria, including using more than intended, failing to cut down, and continuing use despite clear problems. Gabapentin dependence fits this framework, even though the drug is not classified as a controlled substance in most countries.

What makes early identification difficult is that many of the initial signs, running out of medication before a refill is due, asking the prescribing doctor to increase the dose, or feeling anxious when a dose is missed, overlap with the normal experience of someone managing a painful condition. The pattern only becomes clear when multiple signs appear together and when the person's behaviour around the medication starts to change their relationships, their work, or their safety. Understanding the full picture is what dual diagnosis treatment is designed to address.

The behavioural signs of gabapentin misuse tend to emerge before any physical deterioration becomes obvious. Early refill requests are one of the most consistent indicators. A person who is taking more than prescribed will run out before their next dispensing date and find reasons to request early supply: the prescription was lost, they spilled the bottle, they are travelling. Over time this pattern becomes harder to explain away.

Dose escalation is another clear signal. A person managing pain or anxiety at a therapeutic dose will, in most cases, find that dose stable over months. Someone developing dependence often reports that the medication has "stopped working" and requests increases. Repeated dose escalation without a clear clinical reason, particularly when it happens across multiple medical consultations, meets the criteria for doctor-shopping behaviour.

Preoccupation with supply is a third marker. This is the mental bandwidth spent on ensuring access: counting tablets, tracking prescription cycles, researching online dispensing options, or becoming anxious or irritable when supply is uncertain. Gabapentin is not a controlled drug in most countries, which means online availability is high and some people build secondary supply channels alongside their prescriptions.

A psychiatrist at Jintara conducts a full substance use assessment on arrival. When gabapentin is in the mix, that assessment includes a review of prescription history, reported dose versus actual consumption, and the degree to which obtaining or using the drug has become a daily preoccupation. Clients benefit from medically supervised detox when dependence is confirmed.

MedlinePlus gabapentin drug information confirms that gabapentin acts on calcium channels in the central nervous system and produces sedation, dizziness, and impaired coordination at high doses. A person using three to four times the prescribed dose will often show gait disturbance, appearing unsteady on their feet, which family members sometimes mistake for tiredness or an unrelated health issue.

Cognitive impairment is common. At high doses, gabapentin produces noticeable short-term memory difficulties, slowed thinking, and word-finding problems. A person who was previously articulate and organised may begin to lose track of conversations, repeat themselves in the same discussion, or seem mentally foggy at times when their dose peaks.

Sedation during the day and disrupted sleep at night is another pattern. Gabapentin's sedative properties make it attractive for sleep management, but tolerance builds. The person takes more to achieve the same sedative effect, which shifts their sleep architecture and often produces a cycle of daytime sedation and poor overnight sleep.

Withdrawal symptoms when a dose is missed are a definitive physical sign of dependence. These can include sweating, tremor, increased heart rate, and in severe cases, seizure risk, particularly when gabapentin is combined with benzodiazepines or alcohol. Jintara's nursing team monitors gabapentin withdrawal using CNS depressant protocols, with documented shift handovers and regular clinical review through the taper.

The combination with opioids carries particular physical risk. NIDA's overview of prescription CNS depressants documents that gabapentinoids taken alongside opioids substantially increase the risk of respiratory depression. A person using both may not recognise the cumulative sedation risk until they stop breathing safely during sleep, a risk that makes clinical monitoring essential for polysubstance users withdrawing from opioid addiction.

Among people using opioids, gabapentin has become a common adjunct substance. The combination produces two mutually reinforcing effects: gabapentin deepens the euphoric effect of opioids by adding CNS depressant activity, and it reduces the discomfort of early opioid withdrawal. Both effects encourage continued and escalating gabapentin use. Research on gabapentinoid misuse and opioid risk confirms the FDA's 2019 drug safety communication: the gabapentin-opioid combination carries a substantially increased risk of overdose and death, driven by additive respiratory depression.

Recognising this pattern matters because people presenting for opioid detox often do not disclose gabapentin use separately. It is perceived as a prescribed medication, not a drug of concern. When it is not identified at intake, the withdrawal plan accounts only for the opioid, and the gabapentin dependence either goes unmanaged or produces unexpected withdrawal symptoms mid-detox.

At Jintara, the urine drug screen and prescription review on arrival are designed to surface undisclosed substances. Gabapentin does not appear on all standard drug panels, so specific disclosure is important. The intake process includes a direct conversation about all medications in use, not just the primary substance, so the care plan can account for the full picture.

Darren Lockie, Founder: gabapentin use alongside opioids is increasingly common among clients presenting for prescription drug treatment. The psychiatric assessment on arrival identifies co-dependence and sets a taper plan for each substance in sequence. For clients with both opioid dependence and gabapentin dependence, Jintara treats the medical risk of each substance rather than addressing one and leaving the other unmanaged. Managing benzodiazepine dependence presents a similar clinical complexity.

For clients managing withdrawal from both substances simultaneously, the clinical trajectory is rarely linear and rarely comfortable.

Gabapentin addiction is systematically under-recognised in clinical settings because the prescriber-patient relationship frames the drug as a treatment, not a substance of concern. A person seeing multiple doctors for pain or anxiety, each unaware of the others' prescriptions, can accumulate high total daily doses across multiple prescriptions without any single clinician seeing the full picture. This is not deceptive in the criminal sense. It often begins as a genuine attempt to manage unresolved pain or anxiety and gradually becomes a pattern the person themselves does not fully recognise as problematic.

Prescribers are also less alert to gabapentin misuse than to opioid or benzodiazepine misuse, partly because regulatory scrutiny of gabapentin is lower, and partly because the drug's side-effect profile at therapeutic doses is relatively mild. Research published in peer-reviewed literature identifies gabapentin misuse rates of 40 to 65 percent among people already using opioids. Despite this, clinical screening for gabapentin misuse in opioid-using populations remains inconsistent.

The person searching this page is often comparing their own experience against these patterns. They may have noticed that they are running out of gabapentin early, that they feel withdrawal-like symptoms when a dose is missed, or that a family member has raised concern. The fact that it was prescribed does not mean dependence is not real. Gabapentin meets the diagnostic criteria for substance use disorder when use is compulsive, escalating, and continuing despite harm. Jintara's residential treatment program begins with a psychiatric assessment that applies those criteria without judgment.

The psychological dimension of gabapentin addiction is distinct from physical dependence and often persists after the drug is physically cleared. Gabapentin is frequently used to manage underlying anxiety, sleep difficulties, or emotional numbness. When a person discovers that higher doses produce a reliable calming or euphoric effect, that relief becomes psychologically paired with the drug. The brain learns: discomfort arrives, gabapentin resolves it.

Over time, normal levels of stress, which the person previously managed without medication, begin to trigger intense craving for the drug. The threshold for what counts as "unbearable" drops. This is the psychological escalation cycle: use rises not because the condition being treated has worsened, but because the brain's own regulation of discomfort has been altered by repeated chemical intervention.

This cycle is what Darren describes when he says that detox alone does not address the why. "A detox alone does not deal with the why. Most people who do detox end up relapsing pretty quickly because they have not dealt with the reasons they are self-medicating." For gabapentin users, the underlying driver is often unresolved anxiety, chronic pain, or trauma. Treatment that addresses only the gabapentin use without examining the original driver leaves the cycle intact.

Jintara's CBT and EMDR program is designed to identify and work with these underlying drivers during the 30-day program. Clients who understand the psychological cycle are better placed to recognise early warning signs of return to use after discharge. The pre-admission conversation includes a full assessment of co-occurring mental health conditions before a treatment plan is confirmed.

At Jintara, every client who presents with gabapentin in their substance history goes through a psychiatrist-led assessment on arrival. This assessment is not a brief screening. It covers the full picture: what was being taken, at what dose, for how long, what the original prescribing indication was, and what symptoms emerge when a dose is missed or reduced. The assessment also looks for co-occurring conditions, because gabapentin misuse frequently accompanies untreated anxiety, depression, or chronic pain syndromes.

The outcome of the assessment is a taper plan specific to the person's gabapentin dose and dependence level. Abrupt discontinuation of gabapentin at high doses carries seizure risk, particularly in clients also using alcohol or benzodiazepines. A structured taper, managed under daily nursing observation, reduces that risk while keeping the client stable enough to begin therapy.

Lertkhwan Sukpia, Jintara's Psychiatrist, explains that most clients arrive sedated or emotionally flat. As medication takes effect and detox progresses, they may become more emotional. This is not a sign of deterioration. It is a sign that the nervous system is beginning to regulate again. Nursing staff at Jintara monitor this transition closely, with documented shift handovers so every nurse sees the same picture.

The assessment is included in Jintara's standard residential fee, a contrast to facilities that charge separately for psychiatric review. Clients and their families can speak with Lertkhwan Sukpia and the admissions team before arrival to understand what the assessment covers and what to expect in the first 48 hours.